QQQ   355.99 (-1.46%)
AAPL   172.65 (-0.63%)
MSFT   313.63 (-2.54%)
META   301.63 (-1.69%)
GOOGL   133.19 (-0.73%)
AMZN   125.41 (-3.13%)
TSLA   248.51 (-1.23%)
NVDA   440.16 (-1.71%)
NIO   8.73 (-0.68%)
BABA   84.82 (-1.98%)
AMD   101.15 (-2.05%)
T   14.63 (-0.27%)
F   12.10 (-1.71%)
MU   68.68 (+1.06%)
CGC   0.70 (-5.01%)
GE   107.90 (-0.82%)
DIS   80.04 (-2.00%)
AMC   8.10 (-0.61%)
PFE   33.91 (-0.09%)
PYPL   57.75 (-1.38%)
NFLX   378.92 (-0.37%)
QQQ   355.99 (-1.46%)
AAPL   172.65 (-0.63%)
MSFT   313.63 (-2.54%)
META   301.63 (-1.69%)
GOOGL   133.19 (-0.73%)
AMZN   125.41 (-3.13%)
TSLA   248.51 (-1.23%)
NVDA   440.16 (-1.71%)
NIO   8.73 (-0.68%)
BABA   84.82 (-1.98%)
AMD   101.15 (-2.05%)
T   14.63 (-0.27%)
F   12.10 (-1.71%)
MU   68.68 (+1.06%)
CGC   0.70 (-5.01%)
GE   107.90 (-0.82%)
DIS   80.04 (-2.00%)
AMC   8.10 (-0.61%)
PFE   33.91 (-0.09%)
PYPL   57.75 (-1.38%)
NFLX   378.92 (-0.37%)
QQQ   355.99 (-1.46%)
AAPL   172.65 (-0.63%)
MSFT   313.63 (-2.54%)
META   301.63 (-1.69%)
GOOGL   133.19 (-0.73%)
AMZN   125.41 (-3.13%)
TSLA   248.51 (-1.23%)
NVDA   440.16 (-1.71%)
NIO   8.73 (-0.68%)
BABA   84.82 (-1.98%)
AMD   101.15 (-2.05%)
T   14.63 (-0.27%)
F   12.10 (-1.71%)
MU   68.68 (+1.06%)
CGC   0.70 (-5.01%)
GE   107.90 (-0.82%)
DIS   80.04 (-2.00%)
AMC   8.10 (-0.61%)
PFE   33.91 (-0.09%)
PYPL   57.75 (-1.38%)
NFLX   378.92 (-0.37%)
QQQ   355.99 (-1.46%)
AAPL   172.65 (-0.63%)
MSFT   313.63 (-2.54%)
META   301.63 (-1.69%)
GOOGL   133.19 (-0.73%)
AMZN   125.41 (-3.13%)
TSLA   248.51 (-1.23%)
NVDA   440.16 (-1.71%)
NIO   8.73 (-0.68%)
BABA   84.82 (-1.98%)
AMD   101.15 (-2.05%)
T   14.63 (-0.27%)
F   12.10 (-1.71%)
MU   68.68 (+1.06%)
CGC   0.70 (-5.01%)
GE   107.90 (-0.82%)
DIS   80.04 (-2.00%)
AMC   8.10 (-0.61%)
PFE   33.91 (-0.09%)
PYPL   57.75 (-1.38%)
NFLX   378.92 (-0.37%)
NASDAQ:MEIP

MEI Pharma (MEIP) Stock Forecast, Price & News

$6.98
0.00 (0.00%)
(As of 12:55 PM ET)
Compare
Today's Range
$6.77
$6.99
50-Day Range
$5.04
$7.58
52-Week Range
$4.00
$8.68
Volume
11,834 shs
Average Volume
55,137 shs
Market Capitalization
$46.49 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$29.67

MEI Pharma MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
329.3% Upside
$29.67 Price Target
Short Interest
Bearish
4.41% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.49
Upright™ Environmental Score
News Sentiment
0.61mentions of MEI Pharma in the last 14 days
Based on 17 Articles This Week
Insider Trading
Acquiring Shares
$1.05 M Bought Last Quarter
Proj. Earnings Growth
Growing
From ($4.89) to ($4.02) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.26 out of 5 stars

Medical Sector

370th out of 976 stocks

Pharmaceutical Preparations Industry

152nd out of 448 stocks


MEIP stock logo

About MEI Pharma (NASDAQ:MEIP) Stock

MEI Pharma, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor for the treatment of patients with relapsed/refractory follicular lymphoma; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase I clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex which has completed Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer. MEI Pharma, Inc. has a license agreement with Presage Biosciences, Inc. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was incorporated in 2000 and is headquartered in San Diego, California.

MEIP Price History

MEIP Stock News Headlines

Stifel Nicolaus Lowers MEI Pharma (NASDAQ:MEIP) Price Target to $9.00
Buy This Stock for AI Tidal Wave (not NVDA)
The internet boom made more millionaires than any tech  - Microsoft’s CEO says AI has even more potential. Here’s the #1 stock to buy.
Buy This Stock for AI Tidal Wave (not NVDA)
The internet boom made more millionaires than any tech  - Microsoft’s CEO says AI has even more potential. Here’s the #1 stock to buy.
Q4 2023 MEI Pharma Inc Earnings Call
Anson And Cable Car Send Letter to MEI Pharma Stockholders
Anson Funds Management LP Acquires Shares in MEI Pharma Inc
Earnings Outlook For MEI Pharma
MEI Pharma (MEIP) Set to Announce Quarterly Earnings on Tuesday
See More Headlines
Receive MEIP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MEI Pharma and its competitors with MarketBeat's FREE daily newsletter.

MEIP Company Calendar

Last Earnings
11/10/2021
Today
10/03/2023
Next Earnings (Estimated)
11/13/2023
Fiscal Year End
6/30/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:MEIP
Previous Symbol
NASDAQ:MSHL
Employees
46
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$29.67
High Stock Price Forecast
$40.00
Low Stock Price Forecast
$9.00
Forecasted Upside/Downside
+325.0%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
6 Analysts

Profitability

Net Income
$-31,840,000.00
Pretax Margin
-65.22%

Debt

Sales & Book Value

Annual Sales
$48.82 million
Book Value
$3.70 per share

Miscellaneous

Free Float
6,253,000
Market Cap
$46.49 million
Optionable
Optionable
Beta
0.83
5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

  • Mr. David M. Urso B.A. (Age 59)
    Esq., J.D., CEO, Pres & Director
    Comp: $665.65k
  • Dr. Richard G. Ghalie (Age 65)
    Chief Medical Officer
    Comp: $581.53k
  • Mr. Justin J. File (Age 53)
    CFO & Corp. Sec.
  • Mr. Eugene Park
    VP of Marketing
  • Ms. Anne Frese
    Chief People Officer
  • Dr. Robert D. Mass (Age 69)
    Strategic Advisor
  • Mr. David A. Walsey J.D.
    L.L.M., Sr. VP of Corp. Affairs
  • Ms. Yomara Gomez-Naiden
    Sr. VP of Quality













MEIP Stock - Frequently Asked Questions

Should I buy or sell MEI Pharma stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for MEI Pharma in the last year. There are currently 1 sell rating, 4 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" MEIP shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MEIP, but not buy additional shares or sell existing shares.
View MEIP analyst ratings
or view top-rated stocks.

What is MEI Pharma's stock price forecast for 2023?

6 equities research analysts have issued 12-month price objectives for MEI Pharma's shares. Their MEIP share price forecasts range from $9.00 to $40.00. On average, they predict the company's share price to reach $29.67 in the next year. This suggests a possible upside of 325.0% from the stock's current price.
View analysts price targets for MEIP
or view top-rated stocks among Wall Street analysts.

How have MEIP shares performed in 2023?

MEI Pharma's stock was trading at $4.8720 at the beginning of 2023. Since then, MEIP stock has increased by 43.3% and is now trading at $6.98.
View the best growth stocks for 2023 here
.

When is MEI Pharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 13th 2023.
View our MEIP earnings forecast
.

How were MEI Pharma's earnings last quarter?

MEI Pharma, Inc. (NASDAQ:MEIP) released its earnings results on Wednesday, November, 10th. The company reported ($2.60) EPS for the quarter, meeting the consensus estimate of ($2.60). The business had revenue of $13.39 million for the quarter, compared to the consensus estimate of $9.98 million. MEI Pharma had a negative trailing twelve-month return on equity of 92.47% and a negative net margin of 65.22%.

When did MEI Pharma's stock split?

Shares of MEI Pharma reverse split on Monday, April 17th 2023. The 1-20 reverse split was announced on Monday, April 17th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, April 17th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What other stocks do shareholders of MEI Pharma own?
What is MEI Pharma's stock symbol?

MEI Pharma trades on the NASDAQ under the ticker symbol "MEIP."

How do I buy shares of MEI Pharma?

Shares of MEIP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is MEI Pharma's stock price today?

One share of MEIP stock can currently be purchased for approximately $6.98.

How much money does MEI Pharma make?

MEI Pharma (NASDAQ:MEIP) has a market capitalization of $46.49 million and generates $48.82 million in revenue each year. The company earns $-31,840,000.00 in net income (profit) each year or ($4.63) on an earnings per share basis.

How can I contact MEI Pharma?

MEI Pharma's mailing address is 11455 EL CAMINO REAL SUITE 250, SAN DIEGO CA, 92130. The official website for the company is www.meipharma.com. The company can be reached via phone at (858) 369-7100, via email at investor@meipharma.com, or via fax at 302-655-5049.

This page (NASDAQ:MEIP) was last updated on 10/3/2023 by MarketBeat.com Staff

My Account -